A Curve‐Free Method for Phase I Clinical Trials
DOI10.1111/J.0006-341X.2000.00609.XzbMATH Open1060.62611OpenAlexW2080277472WikidataQ52076810 ScholiaQ52076810MaRDI QIDQ4667490FDOQ4667490
Authors: Mauro Gasparini, Jeffrey R. Eisele 
Publication date: 20 April 2005
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/j.0006-341x.2000.00609.x
Recommendations
continual reassessment methodmaximum tolerated dosedose-finding studiesphase I clinical trialtoxicityneutral to the right processproduct-of-beta priors
Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10)
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Tailfree and neutral random probabilities and their posterior distributions
- On the distribution of the product of independent beta random variables
- A Bayesian nonparametric approach to determining a maximum tolerated dose
- Continual Reassessment Method: A Likelihood Approach
Cited In (23)
- Impact of different model structure and prior distribution in continual reassessment method
- Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials
- A comparative study of the dose-response analysis with application to the target dose estimation
- A simple technique to evaluate model sensitivity in the continual reassessment method
- EM-type algorithms for computing restricted MLEs in multivariate normal distributions and multivariatet-distributions
- The treatment versus experimentation dilemma in dose finding studies
- Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors
- On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance
- Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data
- Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
- Bayesian optimal designs for phase I clinical trials
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Continual reassessment method for partial ordering
- Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- Adaptive clinical trial designs for phase I cancer studies
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
- Curve-free and model-based continual reassessment method designs
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
- An application of reinforced urn processes to determining maximum tolerated dose
- Continual reassessment and related dose-finding designs
- Stochastic approximation and modern model-based designs for dose-finding clinical trials
- Design efficiency in dose finding studies
This page was built for publication: A Curve‐Free Method for Phase I Clinical Trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4667490)
